AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
doxribtimine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5787 | 50-89-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Doxribtimine is approved in combination with doxecitine under the name KYGEVVI. The primary mechanism of action of doxecitine and doxribtimine is the incorporation of nucleosides deoxycytidine (dC) and deoxythymidine (dT) into skeletal muscle mitochondrial deoxyribonucleic acid (DNA) to restore mitochondrial DNA copy number and improve skeletal muscle function in patients with TK2d. Doxecitine and doxribtimine likely utilize residual TK2 activity as well as cytosolic phosphorylation pathways such as thymidine kinase 1 and deoxycytidine kinase to increase mitochondrial DNA precursors deoxycytidine triphosphate and deoxythymidine triphosphate in the mitochondria.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 26, 2026 | EMA | UCB Pharma | |
| Nov. 3, 2025 | FDA | UCB Inc |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AX29 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Various alimentary tract and metabolism products |
| CHEBI has role | CHEBI:25212 | metabolite |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
A16AX Various alimentary tract and metabolism products 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Thymidine kinase 2 deficiency | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 2GM/PACKET;2GM/PACKET | KYGEVVI | UCB INC | N219792 | Nov. 3, 2025 | RX | FOR SOLUTION | ORAL | 10471087 | Aug. 7, 2036 | TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS |
| 2GM/PACKET;2GM/PACKET | KYGEVVI | UCB INC | N219792 | Nov. 3, 2025 | RX | FOR SOLUTION | ORAL | 11649259 | Aug. 19, 2040 | TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 2GM/PACKET;2GM/PACKET | KYGEVVI | UCB INC | N219792 | Nov. 3, 2025 | RX | FOR SOLUTION | ORAL | Nov. 3, 2030 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Thymidine kinase | Kinase | IC50 | 5.39 | CHEMBL | |||||
| Thymidylate kinase | Kinase | Ki | 4.57 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| THM | PDB_CHEM_ID |
| CHEMBL52609 | ChEMBL_ID |
| C000732039 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB04485 | DRUGBANK_ID |
| C0040077 | UMLSCUI |
| CHEBI:17748 | CHEBI |
| 11756 | INN_ID |
| D12466 | KEGG_DRUG |
| 5789 | PUBCHEM_CID |
| 44508 | MMSL |
| d10336 | MMSL |
| 005774 | NDDF |
| 4718 | IUPHAR_LIGAND_ID |
| VC2W18DGKR | UNII |
| 1372538 | RXNORM |
| D013936 | MESH_DESCRIPTOR_UI |
| VC2W18DGKR | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| KYGEVVI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50474-350 | POWDER, FOR SOLUTION | 2 g | ORAL | NDA | 28 sections |